Mylan N.V. $6.5 Billion Notes Offering
Davis Polk advised the representatives of the initial purchasers on Rule 144A/Regulation S offerings by Mylan N.V. (“Mylan”) of $1.0 billion aggregate principal amount of its 2.500% senior…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Loxo Oncology, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $41.4 million SEC-registered common stock offering of 1,926,250 shares of common stock of Loxo Oncology, Inc…
Anacor $5.2 billion acquisition by Pfizer
Davis Polk is advising Anacor Pharmaceuticals, Inc. on its approximately $5.2 billion acquisition by Pfizer Inc. The closing of the transaction, which is expected in the third quarter…
AbbVie Inc. Offering of $7.8 Billion Senior Notes
Davis Polk advised the representatives of the underwriters, in connection with an SEC-registered offering by AbbVie Inc. (“AbbVie”) of $7.8 billion aggregate principal amount of senior…
Aeglea BioTherapeutics, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $54.8 million initial public offering by Aeglea BioTherapeutics, Inc. Aeglea’s…
Davis Polk Advises Anacor Pharmaceuticals, Inc. on Its $287.5 Million Convertible Senior Notes Offering and Related Capped Call Transactions
Davis Polk advised Anacor Pharmaceuticals, Inc. in connection with its offering of $287.5 million aggregate principal amount of its 2.00% convertible senior notes due 2023 to qualified…
Corvus Pharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in the $70.5 million initial public offering by Corvus Pharmaceuticals, Inc. of 4,700,000…
Davis Polk Advises Hypermarcas on Debt Tender Offer
Davis Polk advised Hypermarcas S.A. in connection with its cash tender offer to purchase any and all of its outstanding $312.6 million 6.5% senior notes due 2021 and consent solicitation…
NuVasive, Inc. $650 Million Notes Offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NuVasive, Inc. (“NuVasive”) of $650 million aggregate principal amount of its 2.25% convertible senior…
Pfizer Inc. $5 Billion Accelerated Share Repurchase
Davis Polk advised the counterparty in connection with an accelerated share repurchase transaction entered into between the counterparty and Pfizer Inc. (“Pfizer”), pursuant to which Pfizer…